Phase II trial of fulvestrant plus enzalutamide in ER+/HER2− advanced breast cancerAnthony Elias, Jennifer K. Richer, Jennifer R. Diamond et al.|npj Breast Cancer|2023Cited by 16
Clinical and immune responses to neoadjuvant fulvestrant with or without enzalutamide in ER+/Her2− breast cancerAnthony Elias, Jennifer K. Richer, Alyse Staley et al.|npj Breast Cancer|2024Cited by 9
Abstract CT144: Randomized phase II trial of preoperative fulvestrant with or without enzalutamide for ER+/Her2- breast cancerAnthony Elias, Jennifer K. Richer, Alyse Staley et al.|Cancer Research|2023Cited by 0
Abstract PS18-07: Differential odds of response in ILC versus IDC correlate with changes in the TIME in a phase II trial of pre-operative fulvestrant with or without enzalutamideJennifer K. Richer, Dexiang Gao, Anthony Elias et al.|Clinical Cancer Research|2025Cited by 0